Delta-Globin Gene Expression Is Enhanced in vivo by Interferon Type I

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Beta hemoglobinopathies are severe monogenic lethal diseases.
• Delta-globin gene activation is a potential therapeutic strategy.
• Hemoglobin A2 (HbA2), composed of alpha and delta globin chains, has shown therapeutic potential in beta-thalassemia models and anti-sickling effects.

Purpose of the Study:

• To investigate the effect of type 1 interferon (IFNb) on delta-globin expression.
• To explore the potential of IFNb as a modulator of delta-globin levels for therapeutic applications.

Main Methods:

• Analysis of delta-globin mRNA levels in a Deoxyribonuclease II-alpha knockout mouse model with activated IFNb.
• Assessment of beta-globin mRNA levels in the same model.
• Quantification of HbA2 levels in multiple sclerosis patients undergoing type 1 interferon treatment.

Main Results:

• IFNb activation significantly increased delta-globin mRNA levels in fetal liver while decreasing beta-globin mRNA.
• A Deoxyribonuclease II-alpha knockout mouse model exhibited elevated delta-globin mRNA due to IFNb activation.
• Patients with multiple sclerosis treated with type 1 interferon showed significantly increased HbA2 levels.

Conclusions:

• This study demonstrates that delta-globin expression can be enhanced using molecular approaches, specifically via type 1 interferon.
• The findings provide a proof of principle for a pharmacological strategy to increase HbA2 levels.
• This approach holds promise for developing new treatments for beta hemoglobinopathies.